A novel coronavirus has had global impact on individual health and health care delivery. In this C4 article, contributors discuss various aspects of transplantation including donor and recipient screening, management of infected patients, and prevention of coronavirus disease (COVID). Donor screening with SARS-CoV-2 nucleic acid testing (NAT) close to the time of procurement is recommended. Many programs are also screening all potential recipients at the time of admission. The management of COVID has evolved with remdesivir emerging as a new potential option for transplant recipients. Dexamethasone has also shown promise and convalescent plasma is under study. Prevention strategies for transplant candidates and recipients are paramount. Pediatric-specific issues are also discussed. Strategies for the psychological well-being of patients and providers are also imperative, in addition to future research priorities for transplantation.

C4 article: Implications of COVID-19 in transplantation

Gambella, A;
2021-01-01

Abstract

A novel coronavirus has had global impact on individual health and health care delivery. In this C4 article, contributors discuss various aspects of transplantation including donor and recipient screening, management of infected patients, and prevention of coronavirus disease (COVID). Donor screening with SARS-CoV-2 nucleic acid testing (NAT) close to the time of procurement is recommended. Many programs are also screening all potential recipients at the time of admission. The management of COVID has evolved with remdesivir emerging as a new potential option for transplant recipients. Dexamethasone has also shown promise and convalescent plasma is under study. Prevention strategies for transplant candidates and recipients are paramount. Pediatric-specific issues are also discussed. Strategies for the psychological well-being of patients and providers are also imperative, in addition to future research priorities for transplantation.
2021
21
5
1801
1815
clinical research/practice; infection and infectious agents; infection and infectious agents - viral; infectious disease; organ transplantation in general
Aaron, JG; Abbo, LM; Alconchel, F; Amarelli, C; Anjan, S; Ardura, MI; Azar, MM; Azzi, J; Baddley, JW; Balliet, W; Bellini, MI; Blumberg, E; Blumenthal, JA; Bruschwein, HM; Danziger-Isakov, L; Demekhin, V; Dulek, DE; Ferreira, GF; Gambella, A; Giorgakis, E; Gitman, MR; Goff, KL; Green, M; Greenwald, MA; Hand, J; Hemmersbach-Miller, M; Humar, A; Ison, MG; Jaramillo, A; Jesse, MT; Kotton, CN; Kronsnoble, K; Kumar, D; La Hoz, RM; Lentine, K; Lopez, SM; Miko, BA; Mohan, S; Murakami, N; Niles, P; Nolan, A; Nonterah, CW; Park, JM; Madan, RP; Pereira, MR; Villalobos, APC; Pilch, N; Potter, LM; Rodrigue, JR; Schmiedeskamp-Rahe, M; Sharma, D; Sholkamy, A; Singh, N; Tantisattamo, E; Tezer, Y; Theodoropoulos, NM; Truax, C; Valdepenas, B; Verran, D; Westphal, SG; Woodside, KJ
File in questo prodotto:
File Dimensione Formato  
AJT-9999-na.pdf

Accesso riservato

Descrizione: Articolo principale
Tipo di file: PDF EDITORIALE
Dimensione 398.19 kB
Formato Adobe PDF
398.19 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1787616
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 11
social impact